These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29666833)

  • 1. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?
    Isaacs JT
    Am J Clin Exp Urol; 2018; 6(2):55-61. PubMed ID: 29666833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
    Vander Griend DJ; Litvinov IV; Isaacs JT
    Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.
    Antony L; van der Schoor F; Dalrymple SL; Isaacs JT
    Prostate; 2014 Aug; 74(11):1118-31. PubMed ID: 24913829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
    Gao J; Arnold JT; Isaacs JT
    Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
    BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
    Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
    J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.
    Chesire DR; Isaacs WB
    Oncogene; 2002 Dec; 21(55):8453-69. PubMed ID: 12466965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.
    Simanainen U; McNamara K; Gao YR; Handelsman DJ
    Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1335-43. PubMed ID: 19366880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo.
    Yang S; Jiang M; Grabowska MM; Li J; Connelly ZM; Zhang J; Hayward SW; Cates JM; Han G; Yu X
    Oncotarget; 2016 Oct; 7(43):70404-70419. PubMed ID: 27611945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen and prostatic stroma.
    Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
    Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
    Scher HI; Buchanan G; Gerald W; Butler LM; Tilley WD
    Endocr Relat Cancer; 2004 Sep; 11(3):459-76. PubMed ID: 15369448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
    Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.